AndrzejJakubowiak1mhjCqp1G+POmHtvQFPt+2z5/syyp7BaZQ==Andrzej Jakubowiak41.78927490000000-87.601250000000002384Jakubowiak, AndrzejProfessorplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 10000910Authorship 1007568Authorship 1015853Authorship 101667327951230Anderson KC, Jagannath S, Jakubowiak A, Lonial S, Raje N, Schlossman R, Munshi N, Knight R, Esseltine D, Richardson PGJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20; 26(15_suppl):8545.J Clin Oncol2008-05-20T00:00:002008Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM).27601539Stewart AK, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo AJournal of clinical oncology : official journal of the American Society of Clinical OncologyHealth-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 11 10; 34(32):3921-3930.J Clin Oncol2016-11-10T00:00:002016Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.27951178Richardson PG, Lonial S, Jakubowiak A, Jagannath S, Raje N, Avigan D, Ghobrial IM, Knight R, Esseltine D, Anderson KCJournal of clinical oncology : official journal of the American Society of Clinical OncologySafety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol. 2008 May 20; 26(15_suppl):8520.J Clin Oncol2008-05-20T00:00:002008Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study.28211560Dimopoulos MA, Stewart AK, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau PBritish journal of haematologyCarfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 05; 177(3):404-413.Br J Haematol2017-02-17T00:00:002017Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.Authorship 1030837Authorship 103124828415782Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NGOncotargetGlutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876.Oncotarget2017-05-30T00:00:002017Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.28430175Dimopoulos MA, Stewart AK, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo ABlood cancer journalCarfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 04 21; 7(4):e554.Blood Cancer J2017-04-21T00:00:002017Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.D000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsAuthorship 105660128545322Jakubowiak AJ, DeCara JM, Mezzi KHematology (Amsterdam, Netherlands)Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017 Dec; 22(10):585-591.Hematology2017-05-25T00:00:002017Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.D003907Chemicals & Drugs1313260.864765DexamethasoneAuthorship 11111310Authorship 1114508Authorship 1129756Authorship 11595013Authorship 1178061Authorship 1186335Authorship 120426629381435Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AKJournal of clinical oncology : official journal of the American Society of Clinical OncologySelective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866.J Clin Oncol2018-01-30T00:00:002018Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.29027825Jakubowiak AJ, Houisse I, Májer I, Benedict Á, Campioni M, Panjabi S, Ailawadhi SExpert review of hematologyCost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119.Expert Rev Hematol2017-12-01T00:00:002017Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.29231133Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J, ALCYONE Trial InvestigatorsThe New England journal of medicineDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 02 08; 378(6):518-528.N Engl J Med2017-12-12T00:00:002017Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.28546528Luczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld DPolish archives of internal medicineComparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017 06 30; 127(6):392-400.Pol Arch Intern Med2017-05-25T00:00:002017Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.29952705Ailawadhi S, Panjabi S, Campioni M, Majer I, Jakubowiak AJournal of managed care & specialty pharmacyReframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. J Manag Care Spec Pharm. 2018 07; 24(7):711-712.J Manag Care Spec Pharm2018-07-01T00:00:002018Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.29341834Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AKJournal of clinical oncology : official journal of the American Society of Clinical OncologyImprovement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 10; 36(8):728-734.J Clin Oncol2018-01-17T00:00:002018Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.28735890van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca RClinical lymphoma, myeloma & leukemiaPrognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.Clin Lymphoma Myeloma Leuk2017-07-04T00:00:002017Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.Authorship 126363330610196Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial SBlood cancer journalCombining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3.Blood Cancer J2019-01-04T00:00:002019Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.Authorship 112292Authorship 131992Authorship 159174Authorship 1297853Authorship 129795131113777Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau PBloodDaratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.Blood2019-05-21T00:00:002019Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.31124580Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JABritish journal of haematologyPhase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.Br J Haematol2019-05-24T00:00:002019Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.Authorship 129819731142508Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JGClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.Clin Cancer Res2019-05-29T00:00:002019A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.Authorship 19612Authorship 183121Authorship 205882Authorship 19322Authorship 20701Authorship 22932Authorship 180311Authorship 131862331341235Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DSLeukemiaCarfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.Leukemia2019-07-24T00:00:002019Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.Authorship 29052Authorship 132279831420532Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld PBlood cancer journalOprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 08 16; 9(9):66.Blood Cancer J2019-08-16T00:00:002019Oprozomib in patients with newly diagnosed multiple myeloma.Authorship 28021D009842Chemicals & Drugs921790.901828OligopeptidesAuthorship 3348511Authorship 358657Authorship 41773Authorship 1342366Authorship 134255831725894Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz ASBlood advancesResults from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.Blood Adv2019-11-26T00:00:002019Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.31714026Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJCancer medicinePotent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.Cancer Med2019-11-12T00:00:002019Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.Authorship 4461813Authorship 357705Authorship 134713331836199Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel JLancet (London, England)Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.Lancet2019-12-10T00:00:002019Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.Authorship 36691Authorship 3269718Authorship 449951Authorship 3359010Authorship 453727Authorship 461543Authorship 135301531940591Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, Kline JJournal for immunotherapy of cancerRegulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).J Immunother Cancer2020-01-01T00:00:002020Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.Authorship 135406631969330Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martínez-López J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau PClinical cancer research : an official journal of the American Association for Cancer ResearchFirst-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 05 15; 26(10):2308-2317.Clin Cancer Res2020-01-22T00:00:002020First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.Authorship 487901Authorship 384415Authorship 391501Authorship 135752232054831Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KCBlood cancer journalDevelopments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17.Blood Cancer J2020-02-13T00:00:002020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.Authorship 135876532078124Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PLAdvances in therapySplit First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 04; 37(4):1464-1478.Adv Ther2020-02-20T00:00:002020Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.Authorship 136032632094461Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MALeukemiaIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.Leukemia2020-02-24T00:00:002020Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.Authorship 397341Authorship 485811Authorship 1363421032124443Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak ABritish journal of haematologySelinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.Br J Haematol2020-03-02T00:00:002020Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.Authorship 56642Authorship 4442622Authorship 1369042Authorship 1369961632278674Cavo M, Dimopoulos MA, San-Miguel J, Mateos MV, Jakubowiak A, Deraedt W, Lam A, Kampfenkel T, Qi M, He JClinical lymphoma, myeloma & leukemiaComparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):480-489.Clin Lymphoma Myeloma Leuk2020-03-07T00:00:002020Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.32325490Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PGBloodDaratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.Blood2020-08-20T00:00:002020Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.Authorship 4036649Authorship 410544Authorship 49331Authorship 474681Authorship 138171332506429Derman BA, Jasielec JK, Jakubowiak AJBritish journal of haematologyClinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.Br J Haematol2020-06-07T00:00:002020Clinician attitudes and practices toward measurable residual disease in multiple myeloma.Authorship 73483Authorship 487911Authorship 49042Authorship 483615BenjaminDermanBenjamin Derman41.7886000000000087.598699999999993931Derman, BenjaminAssistant ProfessorAuthorship 54793Authorship 60692Authorship 464263Authorship 138759832605900Virani A, Schlei Z, Gleason C, Ackermann M, Wolfe B, Major S, McIver A, Jakubowiak AJ, Jasielec J, Parsad SClinical lymphoma, myeloma & leukemiaImpact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e543-e546.Clin Lymphoma Myeloma Leuk2020-05-04T00:00:002020Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic.Authorship 486431Authorship 496135Authorship 13946821Authorship 139473732712806Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby KOphthalmology and therapyCorneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020 Dec; 9(4):889-911.Ophthalmol Ther2020-07-25T00:00:002020Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.32735641Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJBloodCarfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.Blood2020-11-26T00:00:002020Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.Authorship 13991219Authorship 139932532770051Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BCBlood cancer journalRacial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.Blood Cancer J2020-08-07T00:00:002020Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.32778736Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva BLeukemiaInternational harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.Leukemia2020-08-11T00:00:002020International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Authorship 27681Authorship 348955Authorship 414352Authorship 4412412Authorship 140662732920777Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby KOphthalmology and therapyCorrection to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020 Dec; 9(4):913-915.Ophthalmol Ther2020-12-01T00:00:002020Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.Authorship 490925Authorship 4912848393779Kaiser UB, Jakubowiak A, Steinberger A, Chin WWEndocrinologyRegulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology. 1993 Aug; 133(2):931-4.Endocrinology1993-08-01T00:00:001993Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro.10208431Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SDOncogeneThe t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene. 1999 Mar 04; 18(9):1701-10.Oncogene1999-03-04T00:00:001999The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.KoenVan BesienKoen Van Besien0.000000000000000.000000000000002944Van Besien, KoenPROFESSOR9048630Kaiser UB, Jakubowiak A, Steinberger A, Chin WWEndocrinologyDifferential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology. 1997 Mar; 138(3):1224-31.Endocrinology1997-03-01T00:00:001997Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro.11032826Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SDThe Journal of biological chemistryInhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem. 2000 Dec 22; 275(51):40282-7.J Biol Chem2000-12-22T00:00:002000Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein.11999571Golde DW, Jakubowiak A, Caggiano J, Heaney MLLeukemia & lymphomaCladribine underdosing in hairy-cell leukemia: a cause for apparent response failure. Leuk Lymphoma. 2002 Feb; 43(2):365-7.Leuk Lymphoma2002-02-01T00:00:002002Cladribine underdosing in hairy-cell leukemia: a cause for apparent response failure.Authorship 1420286Authorship 142135433216365Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BCBritish journal of haematologySex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.Br J Haematol2020-11-20T00:00:002020Sex differences in outcomes in multiple myeloma.33162369Derman BA, Kordas K, Molloy E, Chow S, Dale W, Jakubowiak AJ, Jasielec J, Kline JP, Kosuri S, Lee SM, Liu H, Riedell PA, Smith SM, Bishop MR, Artz ASJournal of geriatric oncologyRecommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.J Geriatr Oncol2020-11-05T00:00:002020Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.11122833Jakubowiak A, Cammenga J, Sokolic R, Alvarez S, Jackson G, Hedvat C, Nimer SDCurrent oncology reportsMolecular biology of leukemia. Curr Oncol Rep. 2000 Mar; 2(2):123-31.Curr Oncol Rep2000-03-01T00:00:002000Molecular biology of leukemia.Authorship 142467533271097Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak AThe Lancet. OncologyTreatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540.Lancet Oncol2020-12-01T00:00:002020Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.1722179Janecki A, Jakubowiak A, Steinberger AMolecular and cellular endocrinologyEffects of cyclic AMP and phorbol ester on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment culture. Mol Cell Endocrinol. 1991 Nov; 82(1):61-9.Mol Cell Endocrinol1991-11-01T00:00:001991Effects of cyclic AMP and phorbol ester on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment culture.1794614Jakubowiak A, Janecki A, Tong D, Sanborn BM, Steinberger AMolecular and cellular endocrinologyEffects of recombinant human inhibin and testosterone on gonadotropin secretion and subunit mRNA in superfused male rat pituitary cell cultures stimulated with pulsatile gonadotropin-releasing hormone. Mol Cell Endocrinol. 1991 Dec; 82(2-3):265-73.Mol Cell Endocrinol1991-12-01T00:00:001991Effects of recombinant human inhibin and testosterone on gonadotropin secretion and subunit mRNA in superfused male rat pituitary cell cultures stimulated with pulsatile gonadotropin-releasing hormone.1733048Janecki A, Jakubowiak A, Steinberger AToxicology and applied pharmacologyEffect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological investigations of the "blood-testis" barrier in vitro. Toxicol Appl Pharmacol. 1992 Jan; 112(1):51-7.Toxicol Appl Pharmacol1992-01-01T00:00:001992Effect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological investigations of the "blood-testis" barrier in vitro.Medicine-Hematology and OncologyOphthalmology and Visual Science2169406Janecki A, Jakubowiak A, Steinberger AEndocrinologyVectorial secretion of inhibin by immature rat Sertoli cells in vitro: reexamination of previous results. Endocrinology. 1990 Oct; 127(4):1896-903.Endocrinology1990-10-01T00:00:001990Vectorial secretion of inhibin by immature rat Sertoli cells in vitro: reexamination of previous results.Authorship 144033533535838Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MRLeukemia & lymphomaBloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.Leuk Lymphoma2021-02-03T00:00:002021Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.1908377Janecki A, Jakubowiak A, Steinberger AEndocrinologyRegulation of transepithelial electrical resistance in two-compartment Sertoli cell cultures: in vitro model of the blood-testis barrier. Endocrinology. 1991 Sep; 129(3):1489-96.Endocrinology1991-09-01T00:00:001991Regulation of transepithelial electrical resistance in two-compartment Sertoli cell cultures: in vitro model of the blood-testis barrier.Authorship 144106733563912Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJBlood cancer journalMeasurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.Blood Cancer J2021-02-05T00:00:002021Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.18042711Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, Verhaegen M, Varambally S, Chinnaiyan AM, Jakubowiak AJ, Soengas MSProceedings of the National Academy of Sciences of the United States of AmericaTumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A. 2007 Dec 04; 104(49):19488-93.Proc Natl Acad Sci U S A2007-11-27T00:00:002007Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.2127231Jakubowiak A, Janecki A, Steinberger ABiology of reproductionKinetics of inhibin secretion in static and superfused Sertoli cell cultures in response to follicle-stimulating hormone. Biol Reprod. 1990 Dec; 43(6):939-45.Biol Reprod1990-12-01T00:00:001990Kinetics of inhibin secretion in static and superfused Sertoli cell cultures in response to follicle-stimulating hormone.D009101Disorders823070.737421Multiple Myeloma18685616Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KCLeukemiaThe research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.Leukemia2008-08-07T00:00:002008The research mission in myeloma.18713253Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JLBritish journal of haematologyCharacterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.Br J Haematol2008-08-18T00:00:002008Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.18000495Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NCClinical advances in hematology & oncology : H&OA practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2.Clin Adv Hematol Oncol2007-10-01T00:00:002007A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.18436738Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SNBloodGenomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1993-2003.Blood2008-04-24T00:00:002008Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.19912809Jakubowiak A, Tong D, Janecki A, Sanborn BM, Steinberger AMolecular and cellular neurosciencesPulsatile GnRH stimulation increases steady-state mRNA levels for FSHbeta, LHbeta, and alpha subunits in superfused pituitary cell cultures. Mol Cell Neurosci. 1991 Aug; 2(4):277-83.Mol Cell Neurosci1991-08-01T00:00:001991Pulsatile GnRH stimulation increases steady-state mRNA levels for FSHbeta, LHbeta, and alpha subunits in superfused pituitary cell cultures.20118399Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RAMayo Clinic proceedingsConflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.Mayo Clin Proc2010-02-01T00:00:002010Conflicts of interest, authorship, and disclosures in industry-related scientific publications.2113866Jakubowiak A, Janecki A, Steinberger AEndocrinologyAction kinetics of inhibin in superfused pituitary cells depend on gonadotropin-releasing hormone treatment. Endocrinology. 1990 Jul; 127(1):211-7.Endocrinology1990-07-01T00:00:001990Action kinetics of inhibin in superfused pituitary cells depend on gonadotropin-releasing hormone treatment.19546405Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie BJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol. 2009 Jul 20; 27(21):3510-7.J Clin Oncol2009-06-22T00:00:002009Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).20385792Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KCBloodLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.Blood2010-04-12T00:00:002010Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.17690257Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KCBloodExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.Blood2007-08-09T00:00:002007Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.Authorship 1467422034039952Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak ABlood cancer journalManagement of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021 05 26; 11(5):103.Blood Cancer J2021-05-26T00:00:002021Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).22665938Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij RBloodA phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 Aug 30; 120(9):1801-9.Blood2012-06-04T00:00:002012A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.Authorship 146940334078314Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Jakubowiak A, Doyen C, Lucio P, Nagy Z, Usenko G, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Losava G, Fujisaki T, Garg M, Wang J, Wroblewski S, Kudva A, Gries KS, Fastenau J, San-Miguel J, Cavo MBMC cancerHealth-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 02; 21(1):659.BMC Cancer2021-06-02T00:00:002021Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.22640031Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KCBritish journal of haematologyPerifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.Br J Haematol2012-05-29T00:00:002012Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.22845873Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang MBritish journal of haematologyAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.Br J Haematol2012-07-30T00:00:002012An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.3145931Jakubowiak A, Janecki A, Steinberger AJournal of andrologyTransferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures. J Androl. 1988 Nov-Dec; 9(6):390-6.J Androl1988-11-01T00:00:001988Transferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures.3493166Miskowiak B, Janecki A, Jakubowiak A, Limanowski AExperimental and clinical endocrinologyReproductive functions in the adult male rats after prolonged intraventricular administration of corticotropin-releasing factor (CRF). Exp Clin Endocrinol. 1986 Nov; 88(1):25-30.Exp Clin Endocrinol1986-11-01T00:00:001986Reproductive functions in the adult male rats after prolonged intraventricular administration of corticotropin-releasing factor (CRF).3930311Janecki A, Jakubowiak A, Lukaszyk AMolecular and cellular endocrinologyStimulatory effect of Sertoli cell secretory products on testosterone secretion by purified Leydig cells in primary culture. Mol Cell Endocrinol. 1985 Oct; 42(3):235-43.Mol Cell Endocrinol1985-10-01T00:00:001985Stimulatory effect of Sertoli cell secretory products on testosterone secretion by purified Leydig cells in primary culture.Authorship 147656434175021Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath SLancet (London, England)Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324.Lancet2021-06-24T00:00:002021Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Authorship 147993434269818San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJBloodSustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 01 27; 139(4):492-501.Blood2022-01-27T00:00:002022Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.3133343Janecki A, Jakubowiak A, Steinberger AJournal of andrologyEffect of germ cells on vectorial secretion of androgen binding protein and transferrin by immature rat Sertoli cells in vitro. J Androl. 1988 Mar-Apr; 9(2):126-32.J Androl1988-03-01T00:00:001988Effect of germ cells on vectorial secretion of androgen binding protein and transferrin by immature rat Sertoli cells in vitro.Authorship 148109134274290Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM, Chari AClinical lymphoma, myeloma & leukemiaDaratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):701-710.Clin Lymphoma Myeloma Leuk2021-06-09T00:00:002021Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.21928467Siegel DS, Vij R, Jakubowiak AJClinical advances in hematology & oncology : H&OClinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma. Clin Adv Hematol Oncol. 2011 Apr; 9(4):1-15.Clin Adv Hematol Oncol2011-04-01T00:00:002011Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.22727388Jakubowiak ASeminars in hematologyNovel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction. Semin Hematol. 2012 Jul; 49 Suppl 1:S1-2.Semin Hematol2012-07-01T00:00:002012Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.22727389Jakubowiak ASeminars in hematologyManagement strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012 Jul; 49 Suppl 1:S16-32.Semin Hematol2012-07-01T00:00:002012Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.Authorship 148300234315721Voorhees PM, Jakubowiak AJ, Kumar SK, Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley NJ, Pazdur RClinical cancer research : an official journal of the American Association for Cancer ResearchPerspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. Clin Cancer Res. 2022 01 01; 28(1):23-26.Clin Cancer Res2021-07-27T00:00:002021Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.23040437Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DSClinical lymphoma, myeloma & leukemiaAn open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8.Clin Lymphoma Myeloma Leuk2012-10-01T00:00:002012An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.3610946Janecki A, Jakubowiak A, Steinberger AIn vitro cellular & developmental biology : journal of the Tissue Culture AssociationStudy of the dynamics of Sertoli cell secretions in a new superfusion, two-compartment culture system. In Vitro Cell Dev Biol. 1987 Jul; 23(7):492-500.In Vitro Cell Dev Biol1987-07-01T00:00:001987Study of the dynamics of Sertoli cell secretions in a new superfusion, two-compartment culture system.21990396Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KCJournal of clinical oncology : official journal of the American Society of Clinical OncologyPerifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.J Clin Oncol2011-10-11T00:00:002011Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.Authorship 1495596Authorship 149499334479756Derman BA, Kosuri S, Jakubowiak ABlood reviewsKnowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.Blood Rev2021-08-28T00:00:002021Knowing the unknowns in high risk multiple myeloma.34470049Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EABlood advancesPhase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 10 12; 5(19):3748-3759.Blood Adv2021-10-12T00:00:002021Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.2511933Jakubowiak A, Janecki A, Steinberger ABiology of reproductionSimilar effects of inhibin and cycloheximide on gonadotropin release in superfused pituitary cell cultures. Biol Reprod. 1989 Sep; 41(3):454-63.Biol Reprod1989-09-01T00:00:001989Similar effects of inhibin and cycloheximide on gonadotropin release in superfused pituitary cell cultures.21345726Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PGThe Lancet. OncologyWeekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.Lancet Oncol2011-02-21T00:00:002011Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.21430775Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TRNatureInitial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.Nature2011-03-24T00:00:002011Initial genome sequencing and analysis of multiple myeloma.21477075Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot GEuropean journal of haematologyAlkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.Eur J Haematol2011-06-01T00:00:002011Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.21699382Dytfeld D, Griffith KA, Friedman J, Lebovic D, Harvey C, Kaminski MS, Jakubowiak AJLeukemia & lymphomaSuperior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011 Jul; 52(7):1271-80.Leuk Lymphoma2011-07-01T00:00:002011Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.6276274Janecki A, Lukaszyk A, Jakubowiak AFolia histochemica et cytochemicaCulture of rat Sertoli cells isolated with a modified procedure. Morphological identification of cell population and cell reactivity. Folia Histochem Cytochem (Krakow). 1981; 19(3):135-42.Folia Histochem Cytochem (Krakow)1981-01-01T00:00:001981Culture of rat Sertoli cells isolated with a modified procedure. Morphological identification of cell population and cell reactivity.19738129Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MSJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009 Oct 20; 27(30):5015-22.J Clin Oncol2009-09-08T00:00:002009Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.20497001Cavaletti G, Jakubowiak AJLeukemia & lymphomaPeripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010 Jul; 51(7):1178-87.Leuk Lymphoma2010-07-01T00:00:002010Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.21596852Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine DL, Kelley SL, Kaminski MS, Anderson KC, Richardson PGBloodLenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.Blood2011-05-19T00:00:002011Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.2774218Kowalik I, Kurpisz M, Jakubowiak A, Janecki A, Lukaszyk A, Szymczynski GAndrologiaEvaluation of HLA expression on gametogenic cells isolated from human testis. Andrologia. 1989 May-Jun; 21(3):237-43.Andrologia1989-05-01T00:00:001989Evaluation of HLA expression on gametogenic cells isolated from human testis.22291084Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KCJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5.J Clin Oncol2012-01-30T00:00:002012Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.22555973Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DSBloodAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.Blood2012-05-03T00:00:002012An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.22833546Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath SBloodA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25.Blood2012-07-25T00:00:002012A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Authorship 1514781334871550Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos MThe Lancet. OncologyCarfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 01; 23(1):65-76.Lancet Oncol2021-12-03T00:00:002021Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.Authorship 1531802035210399Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos MV, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Einsele H, Jagannath SBlood cancer journalIncidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022 02 24; 12(2):32.Blood Cancer J2022-02-24T00:00:002022Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.Authorship 15416610Authorship 1542034Authorship 154368135418120Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees PBlood cancer journalDaratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63.Blood Cancer J2022-04-13T00:00:002022Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.35468618Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell EK, Raje N, Cook D, Yee AJ, Logan E, Avigan DE, Jakubowiak A, Shaw K, Daley H, Nikiforow S, Griffin F, Cornwell C, Shen A, Heery C, Maus MVBlood advancesPhase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 03 14; 7(5):768-777.Blood Adv2023-03-14T00:00:002023Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.35462406Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZThe oncologistDaratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 07 05; 27(7):e589-e596.Oncologist2022-07-05T00:00:002022Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.Authorship 1547551035549810Landgren O, Kazandjian D, Roussel M, Jasielec J, Dytfeld D, Anderson A, Kervin TA, Iskander K, McFadden I, Jakubowiak AJLeukemia & lymphomaEfficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 10; 63(10):2413-2421.Leuk Lymphoma2022-05-12T00:00:002022Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.Authorship 1552292635658469Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath SJournal of clinical oncology : official journal of the American Society of Clinical OncologyCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274.J Clin Oncol2022-06-04T00:00:002022Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.Authorship 1554711135732350Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TFJournal for immunotherapy of cancerAntibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).J Immunother Cancer2022-06-01T00:00:002022Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.Authorship 156045235821020Derman BA, Jakubowiak AJ, Thompson MABlood cancer journalClinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.Blood Cancer J2022-07-11T00:00:002022Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.Authorship 1562611535862034Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJJAMA oncologyElotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.JAMA Oncol2022-09-01T00:00:002022Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.Public Health SciencesAuthorship 1584162Authorship 15896622Authorship 1593544Authorship 15986832Authorship 1603566Authorship 16011721Authorship 15860610Authorship 15921122Authorship 1601383035922273Major A, Jakubowiak A, Derman BClinical lymphoma, myeloma & leukemiaLongitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.Clin Lymphoma Myeloma Leuk2022-07-11T00:00:002022Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.36494017Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PMTransplantation and cellular therapyStem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.Transplant Cell Ther2022-12-06T00:00:002022Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.36357295Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath SClinical lymphoma, myeloma & leukemiaPatient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):68-77.Clin Lymphoma Myeloma Leuk2022-10-11T00:00:002022Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.36642080Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJThe Lancet. OncologyCarfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.Lancet Oncol2023-01-12T00:00:002023Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.35974364Chiu BC, Zhang Z, Derman BA, Karpus J, Luo L, Zhang S, Langerman SS, Sukhanova M, Bhatti P, Jakubowiak A, He C, Zhang WJournal of hematology & oncologyGenome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106.J Hematol Oncol2022-08-16T00:00:002022Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma.36358748Wang B, Derman BA, Langerman SS, Johnson J, Zhang W, Jakubowiak A, Chiu BCCancersBody Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Cancers (Basel). 2022 Oct 29; 14(21).Cancers (Basel)2022-10-29T00:00:002022Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma.36546453Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau PHaematologicaAdjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2023 08 01; 108(8):2192-2204.Haematologica2023-08-01T00:00:002023Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.36215989Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schecter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath SThe Lancet. HaematologyHealth-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.Lancet Haematol2022-10-07T00:00:002022Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.36379208Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IMCancer cellImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.Cancer Cell2022-11-14T00:00:002022Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.Authorship 160592936726221Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak AEuropean journal of haematologyA phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.Eur J Haematol2023-02-15T00:00:002023A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.Authorship 1608491136763537Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, Major A, Kin A, Griffith K, Jasielec J, Jakubowiak AJBlood advancesPhase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.Blood Adv2023-10-10T00:00:002023Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.Authorship 161037436799429Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Richardson PG, Voorhees PFuture oncology (London, England)A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2022 Dec; 18(40):4443-4456.Future Oncol2023-02-17T00:00:002023A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.D00006928630750.970216Bortezomibhttps://cgh.uchicago.edu/page/leadershipGlobal Healthhttps://www.uchicagomedicine.org/find-a-physician/physician/olufunmilayo-i-olopadeUChicago Medicinehttps://ophthalmology.uchicago.edu/The University of Chicago Department of Ophthalmologyhttps://cancerbio.uchicago.edu/program/faculty/olufunmilayo-olopadeCancer Biologyhttps://www.uchicagomedicine.org/conditions-services/cancer/cancer-risk-preventionCancer Risk and PreventionUChicagoOVS Authorship 163717537270762Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, Buyukkaramikli N, Phelps H, Slowik R, Pan F, Valluri S, Pacaud L, Jackson GOncology and therapyExtrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncol Ther. 2023 Sep; 11(3):313-326.Oncol Ther2023-06-04T00:00:002023Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.MedicineUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professor37691005Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJBritish journal of haematologyPolyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.Br J Haematol2023-09-10T00:00:002023Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.37621165Kubicki T, Derman BA, Dytfeld D, Jakubowiak AJCurrent opinion in oncologyMeasurable residual disease in peripheral blood in myeloma: dream or reality. Curr Opin Oncol. 2023 11 01; 35(6):574-580.Curr Opin Oncol2023-08-13T00:00:002023Measurable residual disease in peripheral blood in myeloma: dream or reality.37708911Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PGThe Lancet. HaematologyAddition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.Lancet Haematol2023-09-11T00:00:002023Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.Authorship 1661184Authorship 16627325Authorship 16636817Russell Z.SzmulewitzxXFzBrQZHPv5hHlsaUXv9Gq0+s+oRussell Z. Szmulewitz41.78927490000000-87.601250000000001386Szmulewitz, Russell Z.Associate ProfessorBrian Chih-HungChiu1WFhArQ1DO/RmHllZ0mg9mHvBrian Chih-Hung Chiu41.78927490000000-87.601250000000001399Chiu, Brian Chih-HungProfessorAuthorship 1669291437783970Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AMNature medicineElranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576.Nat Med2023-10-02T00:00:002023Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.GiniFleming0GRlDqwcF+v5hHlsaUXv9Gq0+s+oGini Fleming41.78927490000000-87.601250000000001804Fleming, GiniProfessorEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.ProfessorOlufunmilayoOlopade321vBIF1GuTQkntjbwjr93A=Olufunmilayo Olopade41.78927490000000-87.601250000000001960Olopade, OlufunmilayoProfessorAuthorship 167072737827881Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PAClinical lymphoma, myeloma & leukemiaOptimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 Feb; 24(2):83-93.Clin Lymphoma Myeloma Leuk2023-09-16T00:00:002023Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.TheodoreKarrisonTheodore Karrison41.78927490000000-87.601250000000002356Karrison, TheodoreResearch Professor27.45610.00392978437research areas7.617370.046273331coauthor of363.00624.192560similar to11155selected publicationsAmitthaWickrema1nVgCKoHHOHYsW9naE/t8mL1sc65/A==Amittha Wickrema41.78927490000000-87.60125000000000318Wickrema, AmitthaProfessorAuthorship 171019438504552Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes TM, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PGBritish journal of haematologyPost hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Mar 19.Br J Haematol2024-03-19T00:00:002024Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.true1PROFESSORPROFESSORtrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Research ProfessorResearch Professortrue1ProfessorProfessorAuthorship 655701Authorship 662781Authorship 665574Authorship 684116Authorship 692174Authorship 7236910Authorship 740363Authorship 7318319Authorship 766969Authorship 659124Authorship 71209123670297Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath SLeukemiaTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6.Leukemia2013-05-14T00:00:002013Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.24135404Rosenbaum C, Jasielec J, Laubach J, Paba Prada C, Richardson P, Jakubowiak AJSeminars in oncologyEvolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601.Semin Oncol2013-10-01T00:00:002013Evolving strategies in the initial treatment of multiple myeloma.25482145Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, ASPIRE InvestigatorsThe New England journal of medicineCarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 08; 372(2):142-52.N Engl J Med2014-12-06T00:00:002014Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.24135397Jakubowiak AJSeminars in oncologyIntroduction: recent advances in the understanding and management of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):535-6.Semin Oncol2013-10-01T00:00:002013Introduction: recent advances in the understanding and management of multiple myeloma.24429336Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KCBloodA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.Blood2014-01-15T00:00:002014A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.24421329Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KCBloodPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.Blood2014-01-13T00:00:002014Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.24471924Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PGExpert review of hematologyCurrent strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):97-111.Expert Rev Hematol2014-01-29T00:00:002014Current strategies for treatment of relapsed/refractory multiple myeloma.21777223Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KCBritish journal of haematologyMonoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54.Br J Haematol2011-07-21T00:00:002011Monoclonal antibodies in the treatment of multiple myeloma.24630735Jakubowiak AJCancer treatment reviewsEvolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev. 2014 Jul; 40(6):781-90.Cancer Treat Rev2014-03-01T00:00:002014Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.24920586Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial SBloodPhase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14; 124(7):1038-46.Blood2014-06-11T00:00:002014Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.24972772Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJHaematologicaCarfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014 Sep; 99(9):e162-4.Haematologica2014-06-27T00:00:002014Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.Authorship 799941125814533Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJBloodTargeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015 Jun 04; 125(23):3588-97.Blood2015-03-26T00:00:002015Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.Authorship 801731325824111Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJBritish journal of haematologyProteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79.Br J Haematol2015-03-30T00:00:002015Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.Authorship 84486525699653Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DSLeukemia & lymphomaSerum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015; 56(10):2959-61.Leuk Lymphoma2015-05-12T00:00:002015Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Authorship 85138426686406Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S, 1703 study investigatorsThe Lancet. HaematologyElotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.Lancet Haematol2015-11-16T00:00:002015Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.Authorship 85355226561559Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial SClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43.Clin Cancer Res2015-11-11T00:00:002015Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Chicago60637ILAuthorship 857531326637366Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJMolecular cancer therapeuticsSynergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor. Mol Cancer Ther. 2016 Jan; 15(1):60-71.Mol Cancer Ther2015-12-04T00:00:002015Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.Authorship 891851926778538Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PMLancet (London, England)Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.Lancet2016-01-07T00:00:002016Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.Authorship 90158927009059Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KCBloodPhase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.Blood2016-03-23T00:00:002016Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.Authorship 90519127091875Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo ABloodRandomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 06 09; 127(23):2833-40.Blood2016-04-18T00:00:002016Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.AsimFarooqAsim Farooq0.000000000000000.000000000000003355Farooq, AsimAssociate ProfessorPeterRiedellx3BgDqUQFeD5hHlsaUXv9Gq0+s+oPeter Riedell0.000000000000000.000000000000003359Riedell, PeterAssociate ProfessorAuthorship 93262627540718Stefka AT, Park JH, Matsuo Y, Chung S, Nakamura Y, Jakubowiak AJ, Rosebeck SBlood cancer journalAnti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood Cancer J. 2016 08 19; 6(8):e460.Blood Cancer J2016-08-19T00:00:002016Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.Authorship 93524827439911Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špicka I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau PBloodCarfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 09 01; 128(9):1174-80.Blood2016-07-20T00:00:002016Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.Authorship 958395Authorship 953712Authorship 95962127433944Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JLCancerA phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15; 122(21):3327-3335.Cancer2016-07-19T00:00:002016A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.27224006Jakubowiak AJ, Campioni M, Benedict Á, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi SJournal of medical economicsCost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov; 19(11):1061-1074.J Med Econ2016-06-16T00:00:002016Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.24286003Jasielec JK, Jakubowiak AJInternational journal of hematologic oncologyCurrent approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol. 2013 Feb; 2(1).Int J Hematol Oncol2013-02-01T00:00:002013Current approaches to the initial treatment of symptomatic multiple myeloma.Authorship 990812127527861Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MAOncotargetComparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016 Aug 30; 7(35):56726-56736.Oncotarget2016-08-30T00:00:002016Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.